Sinopharm Group Co. Ltd (X2S) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.023x

Based on the latest financial reports, Sinopharm Group Co. Ltd (X2S) has a cash flow conversion efficiency ratio of -0.023x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.63 Billion ≈ $-3.08 Billion USD) by net assets (€113.11 Billion ≈ $132.24 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See X2S cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Sinopharm Group Co. Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Sinopharm Group Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Sinopharm Group Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sinopharm Group Co. Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Mirae Asset Life Insurance Co Ltd KO:085620	0.219x
TIME Dotcom Bhd KLSE:5031	0.104x
NH Hoteles MC:NHH	0.219x
Inesa Intelligent Tech Inc A SHG:600602	-0.009x
PNB Housing Finance Limited NSE:PNBHOUSING	-0.215x
Veracyte Inc NASDAQ:VCYT	0.036x
Air China Limited F:AD2	0.337x
Eclat Textile Co Ltd TW:1476	0.075x

Annual Cash Flow Conversion Efficiency for Sinopharm Group Co. Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Sinopharm Group Co. Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Sinopharm Group Co. Ltd (X2S) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€134.16 Billion ≈ $156.85 Billion	€14.14 Billion ≈ $16.53 Billion	0.105x	+15.63%
2024-12-31	€126.69 Billion ≈ $148.11 Billion	€11.55 Billion ≈ $13.50 Billion	0.091x	-36.15%
2023-12-31	€120.32 Billion ≈ $140.67 Billion	€17.17 Billion ≈ $20.08 Billion	0.143x	-25.06%
2022-12-31	€110.07 Billion ≈ $128.68 Billion	€20.96 Billion ≈ $24.51 Billion	0.190x	+103.91%
2021-12-31	€99.65 Billion ≈ $116.51 Billion	€9.31 Billion ≈ $10.88 Billion	0.093x	-24.68%
2020-12-31	€89.95 Billion ≈ $105.16 Billion	€11.15 Billion ≈ $13.04 Billion	0.124x	-49.19%
2019-12-31	€76.94 Billion ≈ $89.95 Billion	€18.78 Billion ≈ $21.95 Billion	0.244x	+356.05%
2018-12-31	€68.28 Billion ≈ $79.82 Billion	€3.65 Billion ≈ $4.27 Billion	0.054x	-14.49%
2017-12-31	€51.27 Billion ≈ $59.94 Billion	€3.21 Billion ≈ $3.75 Billion	0.063x	-69.90%
2016-12-31	€44.53 Billion ≈ $52.06 Billion	€9.26 Billion ≈ $10.82 Billion	0.208x	-36.64%
2015-12-31	€40.88 Billion ≈ $47.79 Billion	€13.41 Billion ≈ $15.68 Billion	0.328x	+114.12%
2014-12-31	€36.29 Billion ≈ $42.43 Billion	€5.56 Billion ≈ $6.50 Billion	0.153x	-11.27%
2013-12-31	€28.61 Billion ≈ $33.45 Billion	€4.94 Billion ≈ $5.78 Billion	0.173x	--

About Sinopharm Group Co. Ltd

F:X2S Germany Medical Distribution

Market Cap

$2.83 Billion

€2.42 Billion EUR

Market Cap Rank

#5200 Global

#835 in Germany

Share Price

€1.80

Change (1 day)

-1.88%

52-Week Range

€1.80 - €2.37

All Time High

€2.71